Childhood Absence Epilepsy in the Middle Black Sea Region

Year 2021, Volume: 7 Issue: 1, 38 - 41, 30.04.2021

Sevgi Çıraklı

https://doi.org/10.19127/mbsjohs.839024

Abstract

Objective: The aim of this study was to evaluate chilhood absence epilepsy in the Middle Black Sea Region.
Methods: 14 pediatric patients who treated absence epilepsy between May 2018 and May 2020, and had adequate follow-up were included in the study. Medical record datas were reviewed age, gender, etiology, features of family, treatment, and results.
Results: 10 (71%) of the patients were female and 4 (29%) were male. Their average age was 9 years (6-15). Valproate was started in all patients at the time of diagnosis. In the controls 15 days later, no seizure was detected by the family of 5 patients. 5 patients stated that their seizures decreased but continued. In 4 patients, the family did not notice a decrease in seizure frequency. Ethosuximide was added to 9 patients who said that their seizures were still continuing. In the controls 15 days later, 6 patients were found to be cured. However, it was stated that 3 patients had intermittent seizures although they decreased. Lamutrigine was added as the third drug after checking the valproate drug level to these 3 patients, whose treatment was still unsuccessful. 3 patients still have electroencephalography disorder and seizures recognized by the family. With our treatment management, 11 of 14 patients were found to be seizure free.
Conclusion: We achieved high success with valproate and ethosuximide in the treatment management of pediatric absence epilepsy.

Keywords

Absence, epilepsy, childhood, treatment

References

• 1. Loiseau P, Duche B, Pedespan JM. Absence epilepsies. Epilepsia 1995; 36: 1182-1186.
• 2. Galli J, Micheletti S, Malerba L, Fazzi E, Giordano L. Childhood Absence Epilepsy evolving to Eyelid Myoclonia with Absence. Seizure 2018; 61: 1-3.
• 3. Verrotti A, Casciato S, Spalice A, Carotenuto M, Striano P, Parisi P, et al. Coexistence of childhood absence epilepsy and benign epilepsy with centyrotemporal spikes: A case series. Eurepean Journal of Paediatric Neurology 2017; 21: 570-575.
• 4. Kessler SK, McGinnis E. A Practical Guide to Treatment of Childhood Absence Epilepsy. Pediatr Drugs 2019; 21: 15-24.
• 5. Verrotti A, D’Alonzo R, Rinaldi VE, Casciato S, D’Aniello A, Di Gennaro G. Childhood absence epilepsy and benign epilepsy with centro-temporal spikes: a narrative review analysis. World J Pediatr 2017; 13: 106-111.
• 6. Hughs JR. Absence seizures: a review of recent reports with new concepts. Epilepsy Behav 2009; 15: 404-412.
• 7. Cerminara C, Coniglio A, El-Malhany N, Casarelli L, Curatolo P. Two epileptic syndromes, one brain: childhood absence epilepsy and benign childhood epilepsy with centrotemporal spikes. Seizure 2012; 21: 70-74.
• 8. Aigubella Macau M, Falip Centellas M, Veciana de las Heras M, Climent Perin MA, Miro Llado J, Morone Gomez I, et al. Long term prognosis of juvenile absence epilepsy. Neurologia 2011; 26: 193-199.
• 9. Carmant L, Kramer U, Holmes GL, Mikati MA, Riviello JJ, Helmers SL. Differantial diagnosis of staring spells in children: a video-EEG study. Pediatr Neurol 1996; 14: 199-202.
• 10. Larsen J, Johannesen KM, Ek J, Tang S, Marini C, Blichfeldt S, et al. The role of SLC2A1 Mutations in myoclinic astatic epilepsy and absence epilepsy, and the estimated frequency of GLUT1 deficiency syndrome. Epilepsia 2015; 56: 203-208.
• 11. Battino D, Estienne M, Avanzini G. Clinical pharmocokinetics of antiepileptic drugs in paediatric patients. Part I: phenobarbital, primidone, valproic acid, ethosuximide and mesuximide. Clin Pharmocokinet 1995; 29: 257-286.
• 12. Cnaan A, Shinnar S, Arya R, Adamson PC, Clark PO, Dlugos D, et al. Second monotherapy in childhood absence epilepsy. Neurology 2017; 88: 182-190.
• 13. Sato S, Dreifuss FE, Penry JK, Kirby DD, Palesch Y. Long-term follow-up of absence seizures. Neurology 1983; 33: 1590-1595.
• 14. Wirrell EC, Camfield CS, Camfield PR, Gordon KE, Dooley JM. Long-term prognosis of typical childhood absence epilepsy: remission or progression to juvenile myoclonic epilepsy. Neurology 1996; 47: 912-918.
• 15. Kessler SK, Shinnar S, Cnaan A, Dlugos A, Conry J, Hirtz DG, et al. Pretreatment seizure semiology in childhood absence epilepsy. Neurology 2017; 89: 673-679.